Published: Friday, December 14th 2012
(Fierce) - Roche ($RHHBY
) moved a step closer to adding another gem to its crown as the leading provider of therapies against a form of breast cancer. European officials backed approval of the Swiss drug giant's Perjeta
) for use as part of a combo attack on HER2-positive breast cancers.